EW Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.7B
+5.6%
1.6B
+5.0%
1.6B
+1.1%
1.6B
+1.4%
1.5B
Cost of Revenue
392.4M
+8.2%
362.6M
+5.7%
343.0M
-0.6%
345.2M
+0.2%
344.4M
Gross Profit
1.3B
+4.9%
1.3B
+4.8%
1.2B
+1.5%
1.2B
+1.7%
1.2B
Operating Expenses
835.4M
+3.3%
808.4M
-28.4%
1.1B
+29.4%
873.3M
+12.5%
776.6M
R&D
278.9M
+5.9%
263.3M
-1.6%
267.7M
-4.6%
280.7M
+1.6%
276.2M
SG&A
561.2M
+7.5%
522.2M
-13.4%
602.9M
+17.2%
514.6M
+2.5%
502.0M
Operating Income
513.2M
+7.5%
477.6M
+393.4%
96.8M
-71.1%
334.6M
-18.6%
411.2M
EBITDA
562.2M
+1.2%
555.6M
+39.4%
398.7M
-14.1%
464.3M
-1.0%
469.0M
Net Income
241.4M
-36.6%
380.7M
+317.4%
91.2M
-68.6%
290.3M
-12.4%
331.5M
EPS (Basic)
$0.42
-36.4%
$0.66
+312.5%
$0.16
-68.0%
$0.50
-12.3%
$0.57
EPS (Diluted)
$0.42
-36.4%
$0.66
+312.5%
$0.16
-68.0%
$0.50
-10.7%
$0.56
Shares (Diluted)
577.6M
-0.5%
580.7M
-0.2%
581.8M
-0.7%
585.7M
-0.4%
587.9M
Edwards Lifesciences (EW) โ€” Financials